Programa De Acción Específico De Prevención Y Control Del Cáncer: 2021-2024

Objectives

Mexico’s Cancer Prevention and Control Programme seeks to reduce mortality from the country’s main cancers through an integrated, life-course and gender-responsive approach spanning health promotion, primary prevention, organised screening, early diagnosis, diagnostic confirmation, referral, treatment, rehabilitation and palliative care.[1][2]It aims to replace fragmented, cancer-specific responses with coordinated, person-centred cancer control that improves equity, timely access and service quality, particularly for historically discriminated and vulnerable populations.[3][4]

• Strengthen primary prevention by reducing exposure to tobacco, alcohol, unhealthy diets, overweight, obesity, physical inactivity, infectious risks and environmental contaminants, while promoting healthy lifestyles, vaccination and addiction prevention.[5][6]
• Increase early detection nationally through scientifically validated population screening, early recognition of signs and symptoms, targeted case-finding and prompt diagnostic confirmation.[7][4]
• Improve access to timely, appropriate and multidisciplinary treatment for people with confirmed cancer, including psychosocial support, rehabilitation, palliative care, treatment adherence and reintegration into daily and working life where possible.[8][9]
• Strengthen the infrastructure, equipment, supplies and technical capabilities needed for prevention, detection, diagnosis and treatment, with attention to geographical inequalities in specialised personnel and resources.[7][10]
• Establish systematic, comprehensive evaluation and quality-assurance mechanisms that support continuous improvement, transparency and accountability.[7][10]

Priority populations are children and adolescents under 18, women over 18 and men over 18, with cancer information and interventions differentiated by life stage and sex.[2]The programme particularly seeks to avoid preventable harms from diagnostic and treatment errors, overdiagnosis, overtreatment, false-positive and false-negative results.[11][6]Breast and cervical cancer services remain key components, alongside childhood and adolescent cancer control and broader actions for common cancers.[12][13]

Early detection combines screening of apparently healthy people in groups at risk with education for communities and health personnel to recognise warning signs across the life course.[4]Existing screening includes clinical breast examination and biennial mammography for women aged 40 to 69, cervical cytology and high-risk human papillomavirus testing, while a national colorectal cancer screening programme has not yet been developed.[4][8]The programme seeks at least 70% coverage among people eligible for a screening test.[8]

Implementation

Implementation is based on interinstitutional coordination across prevention, detection, diagnosis, referral, treatment, information systems, quality control and resource stewardship.[5][1]The Cancer Prevention and Control Programme oversees the existence, availability, quality and capacity of resources, while healthcare-providing institutions are responsible for acquiring medicines, equipment and specialist personnel.[11][8]Programme actions are financed through the authorised budgets of participating spending executors, although no total budget, allocations, funding gap or financing mechanism is specified.[5]

• Coordinate prevention with the General Directorate of Public Health Policies, the National Commission for Mental Health and Addictions, the National Centre for Vaccination and Child and Adolescent Health, the National Centre for HIV/AIDS/Sexually Transmitted Infections, and environmental health services.[6]
• Link primary care, screening services, diagnostic facilities, specialised oncology centres and hospitals so that suspicious findings receive specialist assessment, histopathological confirmation, referral and treatment without avoidable delay.[1][8]
• Provide childhood and adolescent cancer services through staff training, detection forms for people under 18, diagnostic referral, treatment in specialised units and high-quality case registration.[12]
• Refer confirmed cases to accredited oncology centres or hospitals, verify treatment delivery, record follow-up for at least five years, and provide emotional support, rehabilitation and palliative care.[9]
• Develop and standardise continuous workforce training on cancer risks, referral routes, primary health care, human rights, gender, non-discrimination, inclusion and interculturality, alongside professional certification or recertification.[10][9]
• Maintain an annual national inventory of specialised infrastructure, human resources and equipment, monitor equipment functionality and maintenance, and prioritise corrective action and deployment in higher-incidence communities.[14][10]

National governance involves the Ministry of Health, the Institute of Health for Well-being, the Mexican Social Security Institute, the Institute of Security and Social Services for State Workers, the Institute of Social Security for the Mexican Armed Forces and the Health Services of Petróleos Mexicanos.[15][16]The National Centre for Gender Equity and Reproductive Health leads national policy on breast and cervical cancer, the National Centre for Childhood and Adolescent Health leads childhood and adolescent cancer policy, and the National Centre for Preventive Programmes and Disease Control leads prevention and chronic degenerative disease policy.[17]

Monitoring relies on cancer information systems and administrative records, with the National Centre for Chronic Diseases responsible for reporting several national indicators.[18][19]These include the proportion of probable cancer cases receiving diagnostic confirmation, the proportion of confirmed cases beginning treatment within 30 calendar days, the proportion of specialised equipment that is installed and functional, and the proportion of quality-control programmes implemented.[18][20][19][21]Results of programme performance evaluations are to be published annually on the official websites of National Health System institutions.[14][22]

Quality assurance covers cervical cytology, human papillomavirus testing, colposcopy, mammography acquisition and interpretation, diagnostic ultrasonography, pathology laboratories and other screenable-cancer detection processes.[22]New screening strategies are to be validated, piloted and justified before implementation.[4]The programme also calls for a population-based nominal cancer registry to improve epidemiological intelligence, population targeting and territorial planning.[23]

Monitoring & Evaluation

The programme combines epidemiological surveillance, routine information systems, quality control and annual management indicators to monitor cancer prevention, early detection, treatment access, infrastructure and programme performance. It also seeks to strengthen transparency through publication of results, although several extracts do not specify independent audit arrangements or a fully detailed reporting timetable.[24][10][14][22]

• Monitor cancer incidence, mortality and care processes using national statistics, cancer information systems, administrative records and epidemiological surveillance standards. Mortality tables draw on the “Defunciones 1998-2020 INEGI/SS” source.[25][2][26][27][18][28][29]
• Track screening coverage, diagnostic confirmation, referral, treatment initiation and the quality of cancer records. The programme identifies deficiencies in follow-up, recording screened people, notifying positive results, referral and information tools as barriers to effective care.[12][23][1]
• Establish a population-based nominal cancer registry to improve epidemiological information, population targeting and territorial planning.[23]
• Apply quality controls to prevention, screening, diagnosis and treatment processes to reduce overdiagnosis, overtreatment, false-negative and false-positive results, avoidable harm and inefficient resource use.[11][6][22]
• Standardise quality assurance for cervical cytology, high-risk human papillomavirus testing, colposcopy, mammography acquisition and interpretation, diagnostic ultrasonography, pathology laboratories and detection processes for screenable cancers.[22]
• Evaluate programme indicators systematically, correct delayed or underperforming processes and publish annual performance results on the official websites of National Health System institutions to support transparency and accountability.[10][6][14][22]

Priority Objective 1 uses an annual national management indicator measuring agreements completed appropriately as a proportion of agreements generated. The National Centre for Chronic Diseases within the Health Unit reports the measure, which has an expected upward trend; data are collected from January to December and made available in January.[30]The target series is 80 in 2021, 83 in 2022, 86 in 2023 and 90 in 2024.[31]

Priority Objective 2 measures the proportion of people with a probable cancer case identified through screening or early detection who receive diagnostic confirmation. It is a national annual efficacy indicator, reported by the National Centre for Chronic Diseases using institutional cancer information systems; data are collected from January to December and available in March.[32][18]Diagnostic confirmation may establish either cancer or a negative result.[18]The baseline must be definitive for 2018 or an earlier cycle, but the recorded component values are zero and the accompanying note indicates that no baseline is available.[31][18]

Priority Objective 3 measures the proportion of confirmed cancer cases that begin treatment within 30 calendar days of confirmation. It is a national annual management indicator, with data collected from January to December, available in March, and reported by Health through the National Centre for Chronic Diseases.[20][28]The baseline is recorded as zero for 2018, and targets rise from 75 in 2021 to 80 in 2022, 85 in 2023 and 90 in 2024.[28]

Priority Objective 4 measures the proportion of specialised equipment that is installed and functional, using National Centre for Chronic Diseases administrative records. It is an annual national efficiency indicator with a constant expected trend and an 80 target for each year from 2021 to 2024.[19][29]Priority Objective 5 measures the proportion of quality-control programmes implemented in public National Health System institutions relative to programmes developed for cancer screening and diagnostic confirmation. It is annual, cumulative, efficacy-focused and expected to increase, with targets of 75 in 2021, 80 in 2022, 85 in 2023 and 90 in 2024.[21][33][15]

Observed performance gaps include 65% of childhood and adolescent cancer treatment units recording quality case information in 2018, alongside incomplete evidence on detected cases and treatment initiation despite active case-finding.[12]Screening coverage in 2018 was 24.4% for mammography, 26.7% for clinical breast examination and 46.4% for cervical cancer screening using both tests; coverage subsequently declined during the COVID-19 pandemic.[12][23]The extracts do not specify independent evaluation arrangements, audit procedures, comprehensive surveillance targets or accountability bodies beyond institutional reporting responsibilities and citizen oversight of public planning and budget execution.[11][32][18]

Costing & Financing

Programme actions, including priority objectives, coordination, monitoring and reporting, are to be financed through the authorised budgets of participating spending executors while the programme remains in force.[5]The extracts do not provide a total programme budget, monetary allocations, financing sources, unit costs, costing methodology, quantified funding gap, resource-mobilisation plan or economic assumptions.[17][5][4][8][10]

• Assign healthcare-providing institutions responsibility for acquiring medicines, equipment and specialist personnel, while the Cancer Prevention and Control Programme exercises stewardship over resource existence, availability, quality and capacity.[11][8][10]
• Strengthen infrastructure, equipment, supplies, maintenance and workforce capacity for screening, diagnostic confirmation, follow-up and treatment, including an annual national inventory of specialised resources.[10][14]
• Address insufficient and unevenly distributed human, financial and material resources, including regional disparities in specialised equipment and staff.[23][1]
• Maintain mammography capacity through dedicated, quality-controlled units and trained staff. The stated operational requirement is 1,314 functional units, while Mexico had 1,474 mammography machines in 2016, including 882 in National Health System institutions; their operating status was not specified.[12]

Early detection is expected to reduce the economic and social cost of care, but no quantified estimate is provided.[11][4]Childhood cancer also carries a societal burden: each child who dies from cancer is estimated to lose an average of 70 productive years, in addition to impacts on emotional health and family dynamics.[2][26]The long-term vision links integrated primary-health-care delivery and timely access with potential resource optimisation and lower operating costs, without specifying a monetary value or economic model.[15]